FOXA2 activates HIF2α expression to promote tumor progression and is regulated by the E3 ubiquitin ligase VHL in renal cell carcinoma
Journal of Biological Chemistry · 2024
DOI: 10.1016/j.jbc.2023.105535 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2024. Verfasst von Dongjun Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical …. Hauptthemen laut MEDLINE: Basic Helix-Loop-Helix Proteins, Carcinoma, Renal Cell, Hepatocyte Nuclear Factor 3-beta, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Jiangsu Provincial Department of Science and Technology.
Abstract (Originalsprache)
Renal cell carcinoma (RCC) is a frequent malignancy of the urinary system with high mortality and morbidity. However, the molecular mechanisms underlying RCC progression are still largely unknown. In this study, we identified FOXA2, a pioneer transcription factor, as a driver oncogene for RCC. We show that FOXA2 was commonly upregulated in human RCC samples and promoted RCC proliferation, as evidenced by assays of cell viability, colony formation, migratory and invasive capabilities, and stemness properties. Mechanistically, we found that FOXA2 promoted RCC cell proliferation by transcriptionally activating HIF2α expression in vitro and in vivo. Furthermore, we found that FOXA2 could interact with VHL (von Hippel‒Lindau), which ubiquitinated FOXA2 and controlled its protein stability in RCC cells. We showed that mutation of lysine at position 264 to arginine in FOXA2 could mostly abrogate its ubiquitination, augment its activation effect on HIF2α expression, and promote RCC proliferation in vitro and RCC progression in vivo. Importantly, elevated expression of FOXA2 in patients with RCC positively correlated with the expression of HIF2α and was associated with shorter overall and disease-free survival. Together, these findings reveal a novel role of FOXA2 in RCC development and provide insights into the underlying molecular mechanisms of FOXA2-driven pathological processes in RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The State Key Laboratory of Pharmaceutical Biotechnology, Department of Hematology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, China-Australia Institute of Translational Medicine, School of…
- Department of Urology and Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Medical Biology, The Walter and Eliza Hall Institute of Medical Research, University of Melbourne, Melbourne, Victoria, Australia.
Förderung
- National Natural Science Foundation of China
- Jiangsu Provincial Department of Science and Technology
Zitieren
APA
Yang, D., Li, Q., Lu, P., Wu, D., Li, W., Meng, X., Xing, M., Shangguan, W., Chen, B., Yang, J., Zhang, Z., Wang, Z., Huang, D. C. S., & Zhao, Q. (2024). FOXA2 activates HIF2α expression to promote tumor progression and is regulated by the E3 ubiquitin ligase VHL in renal cell carcinoma. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.105535
Vancouver
Yang D, Li Q, Lu P, Wu D, Li W, Meng X, et al. FOXA2 activates HIF2α expression to promote tumor progression and is regulated by the E3 ubiquitin ligase VHL in renal cell carcinoma. Journal of Biological Chemistry. 2024. doi:10.1016/j.jbc.2023.105535
BibTeX
@article{Yang2024,
author = {Yang, Dongjun and Li, Qixiang and Lu, Peifen and Wu, Dongliang and Li, Wenyang and Meng, Xingjun and Xing, Mengying and Shangguan, Wenbing and Chen, Bing and Yang, Jie and Zhang, Zhihong and Wang, Zengjun and Huang, David C S and Zhao, Quan},
title = {FOXA2 activates HIF2α expression to promote tumor progression and is regulated by the E3 ubiquitin ligase VHL in renal cell carcinoma},
journal = {Journal of Biological Chemistry},
year = {2024},
doi = {10.1016/j.jbc.2023.105535}
}
EUVIMED